IntraBio Reports Statistically Significant and Clinically Meaningful Improvements in the Use of IB1001 For Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease)
August 19, 2021
August 19, 2021
August 19, 2021
July 27, 2021
July 7, 2021
June 8, 2021
February 25, 2021
February 10, 2021
December 16, 2020
December 10, 2020
December 16, 2024
BetaGlue® Therapeutics S.p.A. (“BetaGlue”) an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted ...
December 11, 2024
The Institute of Tissue Medicine of the University of Bern Chooses Indica Labs’ HALO AP® to Become the First Public Health Institute in Switzerland to...
December 10, 2024
Innovative Cell Expansion System Enables Real-Time Metabolic Monitoring and Automated Culture Optimization to Accelerate Cell and Gene Therapy Manufac...
Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225